Get the Stockscreener App
319.49
0.24%
0.76
After Hours:
319.49
Penumbra Inc stock is traded at $319.49, with a volume of 338.83K.
It is up +0.24% in the last 24 hours and up +0.90% over the past month.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
See More
Previous Close:
$318.73
Open:
$318.9
24h Volume:
338.83K
Relative Volume:
0.79
Market Cap:
$12.57B
Revenue:
$1.45B
Net Income/Loss:
$171.05M
P/E Ratio:
73.52
EPS:
4.3459
Net Cash Flow:
$212.73M
1W Performance:
+0.47%
1M Performance:
+0.90%
6M Performance:
-11.10%
1Y Performance:
+37.06%
1-Day Range:
$318.84
$320.48
1-Week Range:
$315.70
$320.48
52-Week Range:
$221.26
$362.41
Penumbra Inc Stock (PEN) Company Profile
Name
Penumbra Inc
Sector
Industry
Phone
(510) 995-2486
Address
ONE PENUMBRA PLACE, ALAMEDA, CA
Compare PEN vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PEN
Penumbra Inc
|
319.49 | 12.54B | 1.45B | 171.05M | 212.73M | 4.3459 |
ABT
Abbott Laboratories
|
104.49 | 179.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
336.74 | 126.60B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
84.22 | 106.51B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
45.51 | 65.77B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
83.04 | 47.58B | 6.30B | 1.07B | 1.09B | 1.8406 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-11-25 | Upgrade | Citigroup | Neutral → Buy |
| Nov-18-25 | Initiated | Wells Fargo | Underweight |
| Oct-08-25 | Upgrade | Needham | Hold → Buy |
| Sep-02-25 | Initiated | Evercore ISI | Outperform |
| Mar-14-25 | Initiated | BofA Securities | Buy |
| Jan-21-25 | Initiated | UBS | Buy |
| Dec-17-24 | Initiated | Oppenheimer | Outperform |
| Dec-11-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-18-24 | Initiated | Stifel | Buy |
| Sep-03-24 | Initiated | Leerink Partners | Outperform |
| Jul-31-24 | Downgrade | Citigroup | Buy → Neutral |
| Jul-31-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-23-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-06-23 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Mar-29-23 | Downgrade | Needham | Buy → Hold |
| Jan-30-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Oct-05-22 | Downgrade | Citigroup | Buy → Neutral |
| Sep-09-22 | Upgrade | Needham | Hold → Buy |
| Jul-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Apr-19-22 | Initiated | Deutsche Bank | Buy |
| Mar-08-22 | Initiated | Needham | Hold |
| Sep-16-21 | Initiated | Truist | Buy |
| Jun-04-21 | Upgrade | BTIG Research | Neutral → Buy |
| Dec-16-20 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-07-20 | Resumed | Canaccord Genuity | Buy |
| Sep-29-20 | Initiated | BTIG Research | Buy |
| Sep-08-20 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| May-30-19 | Upgrade | JP Morgan | Neutral → Overweight |
| May-21-19 | Initiated | William Blair | Outperform |
| Oct-29-18 | Resumed | BofA/Merrill | Buy |
| Oct-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Feb-21-18 | Initiated | William Blair | Outperform |
| Jan-02-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-30-15 | Reiterated | Canaccord Genuity | Buy |
| Oct-13-15 | Initiated | Wells Fargo | Outperform |
View All
Penumbra Inc Stock (PEN) Latest News
Penumbra Inc (PEN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Penumbra Inc (PEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Penumbra Inc (PEN) Income Statement - TradingKey
Penumbra Inc (PEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PEN|Penumbra Inc|Price:318.730|Chg%:+0.760 - TradingKey
Penumbra Market Sentiment - Benzinga España
WHITEBOX ADVISORS LLC's Penumbra Inc(PEN) Holding History - GuruFocus
Penumbra, Inc. (PEN) stock price, news, quote and history - Yahoo Finance Australia
Penumbra (PEN) Following THUNDERBOLT Debut, Is The Stock A Bargain Or Fairly Valued - Yahoo Finance
Penumbra (PEN) Wins FDA Clearance For THUNDERBOLT After Strong Stroke Study - Yahoo Finance
Penumbra, Inc. Revenue Breakdown – BMV:PEN - TradingView
Penumbra, Inc. (PEN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Magnendo Corp. announced that it has received $18 million in funding from Penumbra, Inc. and other investors - marketscreener.com
Magnendo Secures $18M Series A Financing to Transform Endovascular Access for Stroke Intervention - The Manila Times
Penumbra Inc (PEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Penumbra stock reflects growth ambitions amid recent revenue gains - Ad-hoc-news.de
SA JPMorgan Mid-Cap Growth Portfolio's Penumbra Inc(PEN) Holding History - GuruFocus
Penumbra (PEN) Reports THUNDERBOLT Study Success As First Stroke Treatment Use Begins - Sahm
Morningstar Alternatives Fund's Penumbra Inc(PEN) Holding History - GuruFocus
Penumbra’s Thunderbolt stroke device meets study goals By Investing.com - Investing.com South Africa
Penumbra reports THUNDER study results for THUNDERBOLT stroke device - Bitget
Penumbra (PEN) Reports Promising Results for THUNDERBOLT Thrombe - GuruFocus
Penumbra’s Thunderbolt stroke device meets study goals - Investing.com
THUNDER Study Demonstrates Penumbra's THUNDERBOLT is Safe and Effective for Stroke Care - AOL.com
ETFs Investing in Penumbra, Inc. Stocks - TradingView
PEN stock trades steady as Penumbra focuses on growth after recent quarter - Ad-hoc-news.de
Penumbra, Inc. (PEN) Stock forecasts - Yahoo Finance UK
3 Medical Device Stocks Giving Investors a Different Healthcare Play - MarketBeat
Penumbra’s FORWARD Real‑World Stroke Study Might Change The Case For Investing In Penumbra (PEN) - Sahm
Penumbra Inc. Q1 2026 Earnings: EPS Misses Estimates Amid Challenging QuarterMargin Guidance - dars.gov.et
Penumbra Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Penumbra (PEN) Starts The FORWARD Study, Is The Stock Already Expensive? - Sahm
Risk of Antitrust Challenges Remains Low for Boston's Acquisition of Penumbra - Morningstar
Penumbra Inc. (PEN) Q1 2026 Earnings: EPS Misses Estimates by 24.49%, Stock Inches UpCore Business Growth - dars.gov.et
Thunderbolt Computer-Assisted Vacuum Thrombectomy (CAVT) Platform, US - Medical Device Network
Analysts Conflicted on These Healthcare Names: Irhythm Technologies (IRTC), Penumbra (PEN) and Evolus (EOLS) - The Globe and Mail
Penumbra (PEN) Stock Forum and Discussion - Moomoo
(PEN) Volatility Zones as Tactical Triggers - Stock Traders Daily
Price to earnings forward of Penumbra, Inc. – MUN:0P8 - TradingView
Penumbra Expands CAVT for Stroke to Europe with CE Mark for THUNDERBOLT - AOL.com
Enterprise value to EBITDA forward of Penumbra, Inc. – NYSE:PEN - TradingView
Penumbra Deadline Alert - TMX Newsfile
Penumbra starts trial of clot removal device in stroke subgroup - MedTech Dive
Penumbra Inc. (PEN) Holds Steady Near $317 as Traders Eye Key ResistanceAAII Bearish - DonanımHaber
What Is Driving Penumbra (NYSE:PEN) on the NYSE Composite? - Kalkine Media
Penumbra enrolls first patient in distal acute stroke thrombectomy study - MassDevice
Penumbra initiates study on stroke treatment for distal occlusions - Investing.com
First Patient Enrolled in Penumbra's FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke - BioSpace
Penumbra initiates study on stroke treatment for distal occlusions By Investing.com - Investing.com Nigeria
Penumbra (PEN) Launches FORWARD Study to Assess Stroke Treatment Methods - GuruFocus
Penumbra enrolls first patient in stroke study for M2 occlusions - Stock Titan
Penumbra Inc Stock (PEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.79%
4.39%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):